Analysts and investors took to CNBC to discuss the latest action for Johnson & Johnson shares.
Market Movers rounded up the best reactions from investors and analysts on Johnson & Johnson 's latest quarterly results. The experts, including Jim Cramer , discussed the health-care giant as its shares fell 2.8% on Tuesday.
Johnson & Johnson posted first-quarter adjusted earnings and revenue that beat expectations , but dialed back its sales guidance for its pharmaceutical business. Johnson & Johnson is currently held in Jim Cramer's Charitable Trust portfolio.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Alphabet shares dip to start the week. Here's what the experts have to sayAnalysts and investors took to CNBC to discuss the latest action for Alphabet shares.
続きを読む »
Johnson & Johnson beats Q1 consensus estimates and raises guidanceJohnson & Johnson’s stock rose 1.4% in premarket trade Tuesday, after the consumer health and pharma company beat consensus estimates for its first quarter...
続きを読む »
JNJ Stock Price | Johnson & Johnson Stock - Investing.comGet today's JNJ stock price and latest Johnson & Johnson stock news as well as JNJ real-time stock quotes, technical analysis, full financials and more.
続きを読む »
Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 OutlookFirst-quarter earnings were wiped out by a $6.9 billion charge tied to litigation and other costs from its Covid-19 vaccine commitments.
続きを読む »
Stocks making the biggest moves premarket: Johnson & Johnson, Goldman Sachs, Sunrun and moreShares of Goldman Sachs shed nearly 4% after missing revenue estimates in its first-quarter earnings released before Tuesday's opening bell.
続きを読む »
Johnson & Johnson beats on earnings and revenue, raises full-year guidanceEARNINGS: J&J reported adjusted earnings and revenue that topped Wall Street’s expectations, and lifted its full-year forecast. CFO Joseph Wolk joins us to discuss.
続きを読む »